Probiotic effects of Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 on hyperuricemic rats

Abstract

Hyperuricemia is the main cause of gout and involved in the occurrence of multiple diseases, such as hypertension, metabolic disorders and chronic kidney disease. Emerging evidence suggests that lactic acid bacteria (LAB) have shown the beneficial effects on the prevention or treatment of hyperuricemia. In this study, the urate-lowering effect of two LAB strains, Lacticaseibacillus rhamnosus 1155 (LR1155) and Limosilactobacillus fermentum 2644 (LF2644) on hyperuricemic rats were investigated. A hyperuricemic rat model was induced by the intragastric treatment of potassium oxonate, combined with a high purine diet. The oral administration of LR1155, LF2644, or a combination of LR1155 and LF2644 for 4 weeks significantly prevented the rise of the serum uric acid (UA) induced by hyperuricemia. LR1155 and LF2644 significantly elevated the fecal UA levels, increased the UA content and up-regulated gene expression of UA transporter, ATP-binding cassette subfamily G-2 (ABCG2), in colon and jejunum tissues, suggesting the accelerated UA excretion from the intestine. Besides, LR1155 significantly inhibited the activity of xanthine oxidase (XOD) in liver and serum, benefited the reduce of UA production. In addition, LF2644 strengthened the gut barrier functions through an up-regulation of the gene expressions for occluding and mucin2, accompanied with the reduced inflammatory indicators of lipopolysaccharide (LPS) and interleukin-1β (IL-1β) in hyperuricemic rat. Moreover, using 16s rDNA high-throughput sequencing of feces, LR1155 was shown to improve the hyperuricemia induced gut microbial dysbiosis. The genera Roseburia, Butyricicoccus, Prevotella, Oscillibacter, and Bifidobacterium may associate with the effect of LR1155 on microbiota in hyperuricemic rats. Collectively, the results indicated that LR1155 and LF2644 exhibit urate-lowering effects and could be used alone or in combination as a new adjuvant treatment for hyperuricemia.

Priestia megaterium ASC-1 Isolated from Pickled Cabbage Ameliorates Hyperuricemia by Degrading Uric Acid in Rats

“…This may indicate that poor dietary habits or drug injections could potentially impact the liver, even for short periods of time under experimental conditions. Additionally, consistent with previous studies on LR1155 and LF2644, which were isolated from the Xinjiang and Inner Mongolia regions of China, intervention with ASC-1 significantly reduced the renal injury characteristics of hyperuricemia rats, as shown by H&E staining micrographs [48]. These results suggest that ASC-1 can reduce the XOD activity elevated by UA, which may be beneficial for alleviating hyperuricemia.…”

“…This study shows that ASC-1 can effectively reduce MDA and IL-1β levels, effectively degrade nucleosides in the intestine, decrease inflammation, and ultimately alleviate liver and kidney tissue damage. Similar studies have shown that Lacticaseibacillus rhamnosus 1155 and Limosilactobacillus fermentum 2644 can effectively reduce the levels of inflammation and oxidative damage in rats with hyperuricemia [48]. It was discovered that Lactobacillus fermentum F40-4 alleviated the level of liver and kidney damage in hyperuricemia [49].…”

Mechanisms of epigallocatechin gallate (EGCG) in ameliorating hyperuricemia: insights into gut microbiota and intestinal function in a mouse model

“…The potential species- and strain-specific effects of Lactobacillus on regulating the UA excretion transporter genes need further investigation, as the anti-hyperuricemic effects varied among different Lactobacillus strains. 45…”

“…The potential species-and strain-specific effects of Lactobacillus on regulating the UA excretion transporter genes need further investigation, as the anti-hyperuricemic effects varied among different Lactobacillus strains. 45 Previous studies have emphasized the changes of the gut microbiota and their metabolites in the context of improving hyperuricemia. 46,47 In this study, analysis of the cecum contents further demonstrated that EGCG altered the metabolic…”

Exploring substrate–microbe interactions: a metabiotic approach toward developing targeted synbiotic compositions

“…Modes of action include the microbial conversion of uric acid (UA) into allantoin, a more soluble and easily excretable compound, elevation of fecal uric acid excretion via induction of intestinal epithelial excretory UA transporters, and inhibition of xanthine oxidase in the liver and serum of rats. 154 Engineered EcN strains expressing purine- or UA-degrading enzymes ameliorate hyperuricemia in Drosophila melanogaster and rodents. 155 In a study of hyperuricemic gout patients, a Lactobacillus salivarius CECT 30,632 strain derived from screening for purine-degrading efficacy was tested against the standard gout drug allopurinol and resulted in a significant reduction in the number of gout episodes.…”